NEW YORK – Lisen Imprinting Diagnostic (LisenID) on Tuesday said it has entered into an agreement with Mayo Clinic to research and develop diagnostic tests for early cancer detection.

纽约——Lisen Imprinting Diagnostic（LisenID）周二表示，已与梅奥诊所达成协议，共同研究和开发用于早期癌症检测的诊断测试。

The partnership combines LisenID's epigenetic imprinting technology, called QCIGISH (quantitative chromogenic imprinted gene

该合作伙伴关系结合了LisenID的表观遗传印记技术，称为QCIGISH（定量色原印记基因

in situ

原位

hybridization), with Mayo's clinical expertise, Wilmington, Delaware-based LisenID said.

杂交技术），结合梅奥诊所的临床专业知识，位于特拉华州威尔明顿的LisenID公司表示。

QCIGISH is an RNA

QCIGISH 是一种 RNA

in situ

原位

hybridization method that can be used to quantify genomic imprinting alterations that are associated with various cancer types. The company claims on its website that its technology can detect at least 12 types of cancers at their earliest stages.

可以用来量化与各种癌症类型相关的基因组印记改变的杂交方法。该公司在其网站上声称，其技术可以检测至少12种癌症的最早期阶段。

The initial focus of the Mayo collaboration is the research and development of a QCIGISH-based laboratory-developed test for early lung cancer detection using transbronchial needle aspiration samples, the company said. This test aims to provide a more accurate, objective, and clinically actionable tool for diagnosing malignancies in peripheral pulmonary lesions, which are challenging with current cytology-based methods, the company added..

该公司表示，梅奥合作的最初重点是研究和开发基于QCIGISH的实验室开发测试，用于使用经支气管针吸样本进行早期肺癌检测。该公司补充道，该测试旨在为诊断周围性肺部病变的恶性肿瘤提供更准确、客观和临床可操作的工具，而目前基于细胞学的方法在处理这些病变时具有挑战性。

Mayo Clinic has an undisclosed financial interest in the technology, LisenID said. Additional financial details were not disclosed.

梅奥诊所对该技术拥有未披露的财务利益，LisenID 表示。更多财务细节尚未披露。